Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Tax Provisions: 2019-2023

Historic Tax Provisions for Coherus Oncology (CHRS) over the last 2 years, with Sep 2023 value amounting to -$380,000.

  • Coherus Oncology's Tax Provisions was N/A to -$380,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $2.2 million, marking a year-over-year change of. This contributed to the annual value of -$380,000 for FY2023, which is N/A change from last year.
  • As of Q3 2023, Coherus Oncology's Tax Provisions stood at -$380,000, which was down 134.89% from $1.1 million recorded in Q4 2020.
  • In the past 5 years, Coherus Oncology's Tax Provisions ranged from a high of $2.0 million in Q4 2019 and a low of -$380,000 during Q3 2023.
  • Moreover, its 1-year median value for Tax Provisions was -$380,000 (2023), whereas its average is -$380,000.
  • Examining YoY changes over the last 5 years, Coherus Oncology's Tax Provisions showed a top increase of 2,449.02% in 2020 and a maximum decrease of 76.39% in 2020.
  • Over the past 3 years, Coherus Oncology's Tax Provisions (Quarterly) stood at $2.0 million in 2019, then crashed by 46.67% to $1.1 million in 2020, then reached -$380,000 in 2023.
  • Its last three reported values are -$380,000 in Q3 2023, $1.1 million for Q4 2020, and $200,000 during Q3 2020.